BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors Article

Roque, A, Odia, Y. (2017). BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors . 6(2), 95-99. 10.2217/cns-2016-0034

cited authors

  • Roque, A; Odia, Y

authors

abstract

  • We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.

publication date

  • April 1, 2017

Digital Object Identifier (DOI)

start page

  • 95

end page

  • 99

volume

  • 6

issue

  • 2